SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2594[Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells] Ctuck-1/8/2006
2593waiting on: January 2006: Competitor Revlimid (CELG) approval 1H06: Final datmopgcw-1/7/2006
2592SUMMARY ? Millennium today provide 2006 guidance that is overly bullish on VelcaMLNM00-1/7/2006
2591gs: MLNM (IL/N): 1st take: 2006 guidance in-line 52-Week Range US$11-8 YTD Pricmopgcw-1/6/2006
2590The Proteasome Inhibitor Bortezomib (Velcade) Sensitizes Some Human Tumor Cells Icebrg-1/1/2006
2589Erik, I'm not sure that this is a break with the more recent tradition siIan@SI-12/30/2005
2588<i>Millennium to Webcast Business Update in Advance of 24th Annual JPMorgaIcebrg-12/30/2005
2587gs:MLNM (IL/N): Incremental data on Velcade and competition suggest gradual erosmopgcw-12/19/2005
2586<b>Bortezomib Inhibits PKR-Like Endoplasmic Reticulum (ER) Kinase and InduIcebrg-12/18/2005
2585It's Phase 3 for biotech CEO Dunsire makes tough decisions in focusing MillIcebrg-12/16/2005
2584Note that one of the studies is of V with Revlimid after some of the patients weIan@SI-12/12/2005
2583VELCADE(R) (bortezomib) for Injection Continues to Show Impressive Results in a Ian@SI-12/12/2005
2582ATLANTA, Dec. 12 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (NasdaIcebrg-12/12/2005
2581Lenalidomide + Dex for multiple myeloma Message 21963642John McCarthy-12/11/2005
2580Just saw this and have not read it ... but assume you would want to know ... ReJohn McCarthy-12/11/2005
2579New Data Show Median 30-Month Survival With VELCADE(R) (Bortezomib) for InjectioJohn McCarthy-12/11/2005
2578Citigroup:MLNM: Restructuring Underway, But Growth Concerns Remain November mopgcw-12/11/2005
2577As a result of the re-ranking of the NASDAQ-100 Index, the following 12 companieIcebrg-12/10/2005
2576A search for abstracts containing <i>'"Bortezomib"' yielIan@SI-12/7/2005
2575[490] Phase II Study of Bortezomib in Waldenstrom's Macroglobulinemia: ResulIan@SI-12/7/2005
2574[17] Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin's LymphIan@SI-12/7/2005
2573[509] Short Survival, Despite Promising Response Rates, after Bortezomib TreatmeIan@SI-12/7/2005
2572[491] Phase I/II Trial of Bortezomib + CHOP-Rituximab in Diffuse Large B Cell (DIan@SI-12/7/2005
2571[783] Bortezomib Therapy Alone and in Combination with Dexamethasone for PatientIan@SI-12/7/2005
2570[784] Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-ThaIan@SI-12/7/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News